Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE versus MINOXIDIL FOR WOMEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE versus MINOXIDIL FOR WOMEN.
Hydralazine vs MINOXIDIL (FOR WOMEN)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased peripheral vascular resistance and blood pressure. Its exact mechanism is unclear but may involve interference with calcium movement and increased cGMP levels.
Minoxidil is a potassium channel opener. It activates ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arterioles, causing peripheral vasodilation and reduced blood pressure. For hair growth, the exact mechanism is unclear but involves increased cutaneous blood flow, stimulation of hair follicle proliferation via direct effects on dermal papilla cells, and prolongation of the anagen phase.
10-50 mg orally every 6 hours, titrate to maximum 300 mg/day; 10-20 mg intramuscularly or intravenously every 4-6 hours as needed.
Topical: 2% or 5% solution, 1 mL applied to the scalp twice daily (morning and evening).
None Documented
None Documented
Clinical Note
moderateHydralazine + Benzydamine
"Hydralazine may decrease the antihypertensive activities of Benzydamine."
Clinical Note
moderateHydralazine + Droxicam
"Hydralazine may decrease the antihypertensive activities of Droxicam."
Clinical Note
moderateHydralazine + Loxoprofen
"Hydralazine may decrease the antihypertensive activities of Loxoprofen."
Clinical Note
moderateHydralazine + Clonixin
"Hydralazine may decrease the antihypertensive activities of Clonixin."
The terminal elimination half-life of hydralazine is approximately 2-4 hours in patients with normal renal function. However, the duration of antihypertensive effect may be longer (6-12 hours) due to tissue binding and slow release from vascular smooth muscle. In renal impairment, half-life may extend to 7-16 hours, necessitating dose adjustment.
Terminal elimination half-life: approximately 4.2 hours in patients with normal renal function; may extend to 24+ hours in renal impairment.
Hydralazine is primarily metabolized in the liver via N-acetylation and hydroxylation. Approximately 80-90% of the drug is eliminated in urine as metabolites, with less than 10% excreted unchanged. A small fraction appears in feces via biliary excretion.
Primarily renal (90% as unchanged drug and metabolites; 10% via feces via biliary elimination).
Category A/B
Category A/B
Vasodilator
Vasodilator / Hair Growth Stimulant